Page last updated: 2024-11-05

trifluoperazine and Acquired Immunodeficiency Syndrome

trifluoperazine has been researched along with Acquired Immunodeficiency Syndrome in 1 studies

Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pan, G1
Zhou, T1
Radding, W1
Saag, MS1
Mountz, JD1
McDonald, JM1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031]Phase 250 participants (Actual)Interventional2017-10-10Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for trifluoperazine and Acquired Immunodeficiency Syndrome

ArticleYear
Calmodulin antagonists inhibit apoptosis of CD4+ T-cells from patients with AIDS.
    Immunopharmacology, 1998, Volume: 40, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Apoptosis; Calmodulin; CD4-Positive T-Lymphocytes; DNA; Dopamine

1998